Phase 2 TP53 Clinical Trials

7 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 17 of 7 trials

Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 2

ALPINE: Maintenance Letrozole/Abemaciclib

Endometrial CancerTP53Recurrent Endometrial Cancer
Dana-Farber Cancer Institute32 enrolled6 locationsNCT06366347
Recruiting
Phase 2

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

TP53Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University24 enrolled1 locationNCT07240194
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Acute Myeloid LeukemiaTP53
Masonic Cancer Center, University of Minnesota32 enrolled1 locationNCT07008638
Recruiting
Phase 2

Oral-ATO for TP53-mutated Myeloid Malignancies

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Neoplasm+2 more
The University of Hong Kong30 enrolled1 locationNCT06778187
Recruiting
Phase 2

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell LymphomaTP53
The First Affiliated Hospital of Xiamen University52 enrolled1 locationNCT06158399
Recruiting
Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992